Neurocrine reports Q4 INGREZZA sales $615M (+23% YoY); 2025 guidance $2.5-2.6B

NEUROCRINE BIOSCIENCES INC

2024-FY EPS reported $3.29 revenue$2,355,300,000

INGREZZA net product sales $2.3B for FY2024, up 26% YoY; Q4 sales $615M (+23% YoY).
CRENESSITY (crinecerfont) approved Dec 2024 for classic CAH; initial Q4 sales $2M.
Non-GAAP diluted EPS Q4 $1.69 vs $1.54 prior year; GAAP EPS $1.00 vs $1.44 (higher stock-based comp).
2025 INGREZZA sales guidance $2.5-2.6B; Phase 3 osavampator and NBI-568 starting H1 2025.
Completed $300M ASR program in Feb 2025, repurchased ~2.3M shares; cash $1.816B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.